Dabigatran Compared with Warfarin in Patients with Atrial Fibrillation and Symptomatic Heart Failure: A Subgroup Analysis of the RE-LY Trial
The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Abstract
Aims: We evaluated the effects of dabigatran compared with warfarin in the subgroup of patients with previous symptomatic heart failure (HF) in the RE-LY trial. Methods and results: RE-LY compared two fixed and blinded doses of dabigatran (110 and 150 mg twice daily) with open-label warfarin in 18 113 patients with AF at increased risk for stroke. Among 4904 patients with HF, annual rates of stroke or systemic embolism (SE) were 1.92% for patients on warfarin compared with 1.90% for dabigatran 110 mg [hazard ratio (HR) 0.99, 95% confidence interval (CI) 0.69–1.42] and 1.44% for dabigatran 150 mg (HR 0.75, 95% CI 0.51–1.10). Annual rates of major bleeding were 3.90% for the group on warfarin, compared with 3.26% for dabigatran 110 mg (HR 0.83, 95% CI 0.64–1.09) and 3.10% for dabigatran 150 mg (HR 0.79, 95% CI 0.60–1.03). Rates of intracranial bleeding were significantly lower for both dabigatran dosages compared with warfarin in patients with HF (dabigatran 110 mg vs. warfarin, HR 0.34, 95% CI 0.14–0.80; dabigatran 150 mg vs. warfarin, HR 0.39, 95% CI 0.17–0.89). The relative effects of dabigatran vs. warfarin on the occurrence of stroke or SE and major bleeding were consistent among those with and without HF and those with low (≤40%) or preserved (>40%) LVEF (P interaction not significant). Conclusions: The overall benefits of dabigatran for stroke/SE prevention, and major and intracranial bleeding, relative to warfarin in the RE-LY trial were consistent in patients with and without HF.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Dabigatran versus warfarin in patients with atrial fibrillation
Connolly, S. J., Ezekowitz, M. D., Yusuf, S., Eikelboom, J., Oldgren, J., Parekh, A., Pogue, J., Reilly, P. A., Themeles, E., Varrone, J., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0905561 · Cited by 11,215
Lip, G. Y. H., Nieuwlaat, R., Pisters, R., Lane, D. A., & Crijns, H. J. G. M. (2010) · Chest · doi:10.1378/chest.09-1584 · Cited by 6,879
Effect of clopidogrel added to aspirin in patients with atrial fibrillation
The ACTIVE Investigators (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0901301 · Cited by 2,102
Eikelboom, J. W., Wallentin, L., Connolly, S. J., Ezekowitz, M., Healey, J. S., Oldgren, J., Yang, S., Alings, M., Kaatz, S., Hohnloser, S. H., et al. (2011) · Circulation · doi:10.1161/circulationaha.110.004747 · Cited by 1,081
Newly identified events in the RE-LY trial
Connolly, S. J., Ezekowitz, M. D., Yusuf, S., Reilly, P. A., & Wallentin, L. (2010) · New England Journal of Medicine · doi:10.1056/nejmc1007378 · Cited by 688
Self-citationNatural history of asymptomatic left ventricular systolic dysfunction in the community
Wang, T. J., Evans, J. C., Benjamin, E. J., Levy, D., LeRoy, E. C., & Vasan, R. S. (2003) · Circulation · doi:10.1161/01.cir.0000085166.44904.79 · Cited by 633
Gheorghiade, M., & Pang, P. S. (2009) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2008.10.041 · Cited by 600
Diener, H.-C., Connolly, S. J., Ezekowitz, M. D., Wallentin, L., Reilly, P. A., Yang, S., Xavier, D., Di Pasquale, G., & Yusuf, S. (2010) · The Lancet Neurology · doi:10.1016/s1474-4422(10)70274-x · Cited by 451
Self-citation
Research works printed but not linked: 24
- Cleland, 2001, The heart failure epidemic: exactly how big is it?, Eur Heart J, 22, 623, 10.1053/euhj.2000.2493 · DOI · Paper page
- Nieuwlaat, 2009, Atrial fibrillation and heart failure in cardiology practice: reciprocal impact and combined management from the perspective of atrial fibrillation: results of the Euro Heart Survey on atrial fibrillation, J Am Coll Cardiol, 53, 1690, 10.1016/j.jacc.2009.01.055 · DOI
- Maisel, 2003, Atrial fibrillation in heart failure: epidemiology, pathophysiology, and rationale for therapy, Am J Cardiol, 91, 2D, 10.1016/S0002-9149(02)03373-8 · DOI · Paper page
- Dries, 1998, Atrial fibrillation is associated with an increased risk for mortality and heart failure progression in patients with asymptomatic and symptomatic left ventricular systolic dysfunction: a retrospective analysis of the SOLVD trials. Studies of Left Ventricular Dysfunction, J Am Coll Cardiol, 32, 695, 10.1016/S0735-1097(98)00297-6 · DOI · Paper page
- 2007, Stroke in AF working group. Independent predictors of stroke in patients with atrial fibrillation: a systematic review, Neurology, 69, 546, 10.1212/01.wnl.0000267275.68538.8d · DOI · Paper page
- Camm, 2010, Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC), Eur Heart J, 31, 2369, 10.1093/eurheartj/ehq278 · DOI · Paper page
- Camm, 2012, 2012 focused update of the ESC Guidelines for the management of atrial fibrillation. An update of the 2010 ESC Guidelines for the management of atrial fibrillation, Eur Heart J, 33, 2719
- Witt, 2010, Warped Consortium. Twelve-month outcomes and predictors of very stable INR control in prevalent warfarin users, J Thromb Haemost, 8, 744, 10.1111/j.1538-7836.2010.03756.x · DOI
- Lip, 2011, Comparative validation of a novel risk score for predicting bleeding risk in anticoagulated patients with atrial fibrillation: the HAS-BLED (Hypertension, Abnormal Renal/Liver Function, Stroke, Bleeding History or Predisposition, Labile INR, Elderly, Drugs/Alcohol Concomitantly) score, J Am Coll Cardiol, 57, 173, 10.1016/j.jacc.2010.09.024 · DOI · Paper page
- DiMarco, 2005, AFFIRM Investigators. Factors affecting bleeding risk during anticoagulant therapy in patients with atrial fibrillation: observations from the Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) study, Am Heart J, 149, 650, 10.1016/j.ahj.2004.11.015 · DOI · Paper page
- Cleland, 2007, Prevalence of markers of heart failure in patients with atrial fibrillation and the effects of ximelagatran compared to warfarin on the incidence of morbid and fatal events: a report from the SPORTIF III and V trials, Eur J Heart Fail, 9, 730, 10.1016/j.ejheart.2007.01.013 · DOI
- Ezekowitz, 2009, Rationale and design of RE-LY: randomized evaluation of long-term anticoagulant therapy, warfarin, compared with dabigatran, Am Heart J, 157, 805, 10.1016/j.ahj.2009.02.005 · DOI · Paper page
- Wallentin, 2010, on behalf of the RE-LY investigators. Efficacy and safety of dabigatran compared with warfarin at different levels of international normalised ratio control for stroke prevention in atrial fibrillation: an analysis of the RE-LY trial, Lancet, 376, 975, 10.1016/S0140-6736(10)61194-4 · DOI · Paper page
- Oldgren, 2012, on behalf of the RE-LY Investigators. Risks for stroke, bleeding, and death in patients with atrial fibrillation receiving dabigatran or warfarin in relation to the CHADS2 score: a subgroup analysis of the RE-LY trial, Ann Intern Med, 155, 660, 10.7326/0003-4819-155-10-201111150-00004 · DOI · Paper page
- Gage, 2001, Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation, JAMA, 285, 2864, 10.1001/jama.285.22.2864 · DOI · Paper page
- Mulder, 2012, Stroke aetiology in heart failure: towards patient-tailored prevention of stroke, Eur J Heart Fail, 14, 230, 10.1093/eurjhf/hfs018 · doi:10.1093/eurjhf/hfs018
- Ogilvie, 2010, Underuse of oral anticoagulants in atrial fibrillation: a systematic review, Am J Med, 123, 638, 10.1016/j.amjmed.2009.11.025 · DOI · Paper page
- Ahmad, 2012, New oral anticoagulants for stroke prevention in atrial fibrillation: impact of gender, heart failure, diabetes mellitus and paroxysmal atrial fibrillation, Expert Rev Cardiovasc Ther, 10, 1471, 10.1586/erc.12.148 · DOI · Paper page
- Choudry, 2006, Impact of adverse events on prescribing warfarin in patients with atrial fibrillation: matched pair analysis, BMJ, 332, 141, 10.1136/bmj.38698.709572.55 · DOI · Paper page
- Ferrari, 2007, for the ALPHA Study Group. Atrial fibrillation in heart failure patients: prevalence in daily clinical practice and effect on the severity of symptoms. Data from the ALPHA study registry, Eur J Heart Fail, 9, 502, 10.1016/j.ejheart.2006.10.021 · DOI
- Bourlag, 2011, Heart failure with preserved ejection fraction: pathophysiology, diagnosis, and treatment, Eur Heart J, 32, 670, 10.1093/eurheartj/ehq426 · DOI · Paper page
- Banerjee, 2012, Ejection fraction and outcomes in patients with atrial fibrillation and heart failure: the Loire Valley Atrial Fibrillation Project, Eur J Heart Fail, 14, 295, 10.1093/eurjhf/hfs005 · DOI · Paper page
- Huisman, 2012, Dabigatran etexilate for stroke prevention in patients with atrial fibrillation: resolving uncertainties in routine practice, Thromb Haemost, 107, 838, 10.1160/TH11-10-0718 · DOI · Paper page
- Yusuf, 1993, Design, results and interpretation of randomized, controlled trials in congestive heart failure and left ventricular dysfunction, Circulation, 87(Suppl. VII), 115
Cited by
Heidenreich, P. A., Bozkurt, B., Aguilar, D., Allen, L. A., Byun, J. J., Colvin, M. M., Deswal, A., Drazner, M. H., Dunlay, S. M., Evers, L. R., et al. (2022) · Circulation · doi:10.1161/cir.0000000000001063 · Cited by 4,922
2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure
Heidenreich, P. A., Bozkurt, B., Aguilar, D., Allen, L. A., Byun, J. J., Colvin, M. M., Deswal, A., Drazner, M. H., Dunlay, S. M., Evers, L. R., et al. (2022) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2021.12.012 · Cited by 2,862
2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: Executive Summary
Heidenreich, P. A., Bozkurt, B., Aguilar, D., Allen, L. A., Byun, J. J., Colvin, M. M., Deswal, A., Drazner, M. H., Dunlay, S. M., Evers, L. R., et al. (2022) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2021.12.011 · Cited by 931
Heidenreich, P. A., Bozkurt, B., Aguilar, D., Allen, L. A., Byun, J. J., Colvin, M. M., Deswal, A., Drazner, M. H., Dunlay, S. M., Evers, L. R., et al. (2022) · Circulation · doi:10.1161/cir.0000000000001062 · Cited by 394
Abuknesha, N. R., O’Keefe, J. H., Qian, F., Tintle, N. L., Lin, Y., Sun, Y., Qian, H.-Z., Aisen, P. S., Albert, C. M., Aronson, W. J., et al. (2026) · Circulation: Arrhythmia and Electrophysiology · doi:10.1161/circep.125.014785 · Cited by 1
Metadata
- Authors
- Ferreira, J., Ezekowitz, M. D., Connolly, S. J., Brueckmann, M., Fraessdorf, M., Reilly, P. A., Yusuf, S., & Wallentin, L.
- Venue
- European Journal of Heart Failure
- Publisher
- Oxford University Press (OUP)
- Published
- 2013-09-01
- Volume
- 15
- Issue
- 9
- Pages
- 1053-1061
- ISSN
- 1388-9842 (ISSN-L)
- 1879-0844
- OpenAlex
- W2007272937
- Cited by
- 98
- References
- 8
- FWCI
- 8.47
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Dabigatran Compared with Warfarin in Patients with Atrial Fibrillation and Symptomatic Heart Failure: A Subgroup Analysis of the RE-LY Trial. https://app.cochat.ai/papers/10.1093/eurjhf/hft111
- The paper
- Ferreira, J., Ezekowitz, M. D., Connolly, S. J., Brueckmann, M., Fraessdorf, M., Reilly, P. A., Yusuf, S., & Wallentin, L. (2013). Dabigatran Compared with Warfarin in Patients with Atrial Fibrillation and Symptomatic Heart Failure: A Subgroup Analysis of the RE-LY Trial. European Journal of Heart Failure. https://doi.org/10.1093/eurjhf/hft111
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.